Overview

Next Generation Sequencing-based "Oncochip" for Therapeutic Decision in Metastatic Breast Cancer. Study SHARP

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

The present trial clinical proposes to randomize patients with cancer metastatic disease of the breast progressing on standard therapy to receive a treatment selected from 4 "targeted" drugs (a MEK kinase inhibitor, an mTOR kinase inhibitor, an of the enzyme involved in DNA repair PARP and an androgen receptor inhibitor) on the basis of possible presence of mutations in a panel of 61 genes analyzed on metastatic tissue from biopsy, or receive standard chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

European Institute of Oncology

Treatments:

Drug Therapy